Roche obtained an exclusive worldwide license to Rona Therapeutics’ investigational ALK7-targeting RNA interference program for obesity and metabolic disease. Rona is eligible for up to $100 million in combined upfront and near-term milestone payments,…
Novo Nordisk licensed ex-China-region rights to Hengrui’s HRS-1596, a Phase 1-ready oral GLP-1/GIP dual-receptor agonist designed for once-weekly dosing in obesity and type 2 diabetes. Hengrui will receive $300 million upfront and may receive…
Viking reported that participants switching from weekly VK2735 induction to every other week dosing maintained an average 90 percent of prior weight loss over 12 weeks, while monthly dosing maintained 85 percent versus 61…
Novo Nordisk acquired three early-stage non-incretin obesity programs from Kallyope, including IND-ready peptide K-554, a follow-on small molecule against an undisclosed novel target, and a separate small-molecule receptor agonist. Financial terms and specific targets…
John P. Sharp resigned as Skye Bioscience’s chief financial officer and principal financial and accounting officer effective September 8. The board appointed president and chief executive officer Punit Dhillon as principal financial and accounting…
Moonwalk Biosciences closed an oversubscribed $70 million Series B co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures….
Superluminal Medicines closed an oversubscribed $60 million Series B led by BVF Partners, with new participation from Deep Track Capital and Perceptive Advisors and follow-on support from RA Capital, Insight Partners, NVIDIA, Catalio, Eli…
iBio appointed endocrinologist Molly Carr, M.D., as chief medical officer effective July 31, 2026 and announced the appointment on August 4. She will lead global clinical strategy, medical affairs and regulatory work as the…
GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction.
